Get the Stockscreener App
2.69
3.93%
-0.11
After Hours:
2.68
-0.010
-0.37%
Nrx Pharmaceuticals Inc stock is traded at $2.69, with a volume of 467.13K.
It is down -3.93% in the last 24 hours and up +0.00% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.80
Open:
$2.85
24h Volume:
467.13K
Relative Volume:
0.43
Market Cap:
$45.50M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.6725
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-24.23%
1M Performance:
+0.00%
6M Performance:
+26.89%
1Y Performance:
-29.02%
1-Day Range:
$2.67
$2.95
1-Week Range:
$2.67
$3.65
52-Week Range:
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.69 | 45.50M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals, Inc. announced that it expects to receive $1.999998 million in funding from JGS Holdings LLC - Marketscreener.com
Mental Health Revolution: HOPE's $27M Backed Ketamine Clinic Network Takes Shape With BTIG Partnership - StockTitan
HOPE Therapeutics and NRx Pharmaceuticals Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - citybiz
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding - MSN
SEC Form 424B3 filed by NRX Pharmaceuticals Inc. - Quantisnow
NRx secures $27 million for mental health clinic expansion By Investing.com - Investing.com South Africa
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Biotech Soars On Large Investment Announcement Into Its Subsidiary - The Globe and Mail
TSX American Preferred Stock Index (STNC) QuotePress Release - The Globe and Mail
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
NRX Pharmaceuticals Unit Secures $27 Million Funding; Shares Jump -January 28, 2025 at 02:50 pm EST - Marketscreener.com
What's Going On With NRX Pharmaceuticals Stock Tuesday?NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga
NRx secures $27 million for mental health clinic expansion - Investing.com
NRx Pharmaceuticals announces $3.5M registered direct offering - TipRanks
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - StreetInsider.com
NRx Pharma's $8.9M Deal Unlocks Path to FDA Approval for Revolutionary Depression Treatments - StockTitan
Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) - The Globe and Mail
Transforming Mental Health Treatments and Expanding Clinic - openPR
NRx Pharmaceuticals Regains Compliance With Nasdaq Minimum Market Value - citybiz
NRX Pharmaceuticals Board Changes and Nasdaq Compliance - TipRanks
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With - GuruFocus.com
NRx Pharmaceuticals Regains Nasdaq Compliance, Confirms Listing Security - StockTitan
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
NRx Pharma unit to acquire psychiatric facility Kadima - MSN
NRx Pharmaceuticals Appoints Michael Taylor To Board - citybiz
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc. - Quantisnow
NRx Pharmaceuticals Strengthens Board with Key Financial and Healthcare Veterans After $27M Deal - StockTitan
NRx Pharmaceuticals Board Member Resigns, New Member to be Appointed - Defense World
NRx Pharmaceuticals director resigns, new nominee expected By Investing.com - Investing.com Australia
NRx Pharmaceuticals director resigns, new nominee expected - Investing.com
NRx Pharmaceuticals, Inc. Announces the Resignation of Janet Rehnquist as A Member of the Board - Marketscreener.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel - StreetInsider.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market - Quantisnow
NRx Pharmaceuticals Pursues NASDAQ Global Market Uplisting to Boost Institutional Access - StockTitan
NRx Pharmaceuticals, Inc. announced that it expects to receive $2.0002 million in funding -January 04, 2025 - Marketscreener.com
NRx Pharmaceuticals Announces Entry into Share Purchase Agreement with HOPE Therapeutics and JGS Holdings LLC - Defense World
NRXPNRX Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club - The Eastern Progress Online
NRx Pharmaceuticals Secures $25M Backing for Massive Mental Health Clinic Expansion - StockTitan
D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - Defense World
Best Momentum Stocks to Buy for January 6th - MSN
Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations, Plus New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP - Barchart
Stock market news: Hoth Therapeutics +184.32%, DatChat +79.85% among top gainers during mid day trading - Business Upturn
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventiona - StreetInsider.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTS - PR Newswire
Agreement for $27 Million in Funding for Expanding Clinic - openPR
NRx stock rallies 35% on equity purchases, clinic acquisition - MSN
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:N - GuruFocus.com
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):